[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Beam Therapeutics Inc (BEAM)

Beam Therapeutics Inc (BEAM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,320,751
  • Shares Outstanding, K 102,746
  • Annual Sales, $ 139,740 K
  • Annual Income, $ -79,990 K
  • EBIT $ -384 M
  • EBITDA $ -377 M
  • 60-Month Beta 2.26
  • Price/Sales 23.14
  • Price/Cash Flow N/A
  • Price/Book 2.58

Options Overview Details

View History
  • Implied Volatility 94.17% (+5.72%)
  • Historical Volatility 73.96%
  • IV Percentile 77%
  • IV Rank 59.34%
  • IV High 122.94% on 02/11/26
  • IV Low 52.20% on 08/06/25
  • Expected Move (DTE 4) 2.49 (7.71%)
  • Put/Call Vol Ratio 0.09
  • Today's Volume 380
  • Volume Avg (30-Day) 475
  • Put/Call OI Ratio 0.27
  • Today's Open Interest 14,773
  • Open Int (30-Day) 14,250
  • Expected Range 29.83 to 34.81

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 19 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.99
  • Number of Estimates 6
  • High Estimate $-0.93
  • Low Estimate $-1.16
  • Prior Year $-1.00
  • Growth Rate Est. (year over year) +1.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
25.20 +28.25%
on 04/09/26
32.49 -0.52%
on 05/07/26
+6.88 (+27.04%)
since 04/08/26
3-Month
21.63 +49.42%
on 03/30/26
34.20 -5.50%
on 02/25/26
+5.80 (+21.87%)
since 02/06/26
52-Week
15.35 +110.55%
on 05/30/25
36.44 -11.31%
on 01/12/26
+15.07 (+87.36%)
since 05/08/25

Most Recent Stories

More News
Beam Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates

Recent BEAM-302 Topline Data in Alpha-1 Antitrypsin Deficiency (AATD) Demonstrate Strong Single-dose Safety and Efficacy Profile, with 60 mg Selected as Optimal Biological Dose; Global Pivotal Cohort Expected...

BEAM : 32.32 (+2.70%)
Beam Therapeutics Reports Tomorrow, but the Pipeline Questions Linger Louder Than Ever

Barchart Research What to Expect from BEAM Earnings BEAM Generated May 4, 2026 Current Price $30.08 EPS Estimate $$-0.87 Consensus Rating Strong Buy Average Move 6.00% Beam Therapeutics Reports Tomorrow,...

BEAM : 32.32 (+2.70%)
3 Biotech Stocks That Could Benefit from the Patent Cliff

Biotech M&A is surging ahead of a $300B patent cliff. Here are 3 gene-editing stocks investors are watching as potential acquisition targets

BEAM : 32.32 (+2.70%)
CRSP : 54.83 (+4.60%)
MRK : 111.38 (-0.82%)
BMY : 56.16 (-0.16%)
NTLA : 14.09 (+2.77%)
Beam Therapeutics Announces Publication of BEACON Phase 1/2 Data for risto-cel in Patients with Sickle Cell Disease (SCD) in The New England Journal of Medicine

Prestigious Publication Reinforces risto-cel’s Durable, Differentiated Clinical Data for the Treatment of SCD with Severe Vaso-occlusive Crises (VOCs) Initially Presented at ASH, Data from 31...

BEAM : 32.32 (+2.70%)
Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development

Treatment with 60 mg of BEAM-302 Led to Mean Steady-state Total AAT Level of 16.1 µM and All Patients Consistently and Durably Above the 11 µM Protective AAT Threshold with up to 12 Months of Follow-up...

BEAM : 32.32 (+2.70%)
Beam Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Announces New Liver-Targeted Genetic Disease Program in Phenylketonuria (PKU)

New Program Designed as Platform-based Approach for Direct Correction of Mutations Causing PKU; Investigational New Drug (IND) Filing for BEAM‑304 Anticipated in 2026 Updated Phase 1/2 Data and...

BEAM : 32.32 (+2.70%)
Beam Therapeutics Announces $500 Million Strategic Financing Facility with Sixth Street

$100 Million Funded at Close with up to an Additional $400 Million Available Under Facility with Seven-Year Term Financing Bolsters Balance Sheet with Long-term, Non-dilutive Capital to Support Anticipated...

BEAM : 32.32 (+2.70%)
Beam Therapeutics to Host Investor Webcast for Fourth Quarter and Year-End 2025 Financial Results and New Liver-targeted Genetic Disease Program

CAMBRIDGE, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...

BEAM : 32.32 (+2.70%)
Cathie Wood Just Bet $26 Million on Broadcom Stock. Should You Buy AVGO Too?

Cathie Wood bets on Broadcom while shorting major market names in a week of activity.

BLSH : 43.66 (+5.97%)
ARKX : 34.34 (+4.54%)
NFLX : 87.49 (-0.86%)
META : 609.63 (-1.16%)
ROKU : 129.53 (+2.26%)
TXG : 21.60 (-3.66%)
GTLB : 25.98 (+0.23%)
AVGO : 430.00 (+4.23%)
TWST : 56.85 (-2.89%)
ILMN : 141.88 (+2.29%)
CRCL : 113.67 (+0.37%)
WRD : 7.51 (+1.62%)
Beam Therapeutics Sets Strategic Priorities for its Genetic Disease and Hematology Franchises to Drive Execution of Late-Stage Clinical Programs and Extends its Operating Runway through Commercial Transition

Alignment Reached with U.S. FDA on Potential Accelerated Approval Pathway for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) Based on Biomarker Endpoints U.S. B iologics Licensing Application...

BEAM : 32.32 (+2.70%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Beam Therapeutics Inc. is a biotechnology company. It engages in developing precision genetic medicines through base editing. Beam Therapeutics Inc. is based in Cambridge, Massachusetts.

See More

Key Turning Points

3rd Resistance Point 34.45
2nd Resistance Point 33.46
1st Resistance Point 32.89
Last Price 32.32
1st Support Level 31.33
2nd Support Level 30.34
3rd Support Level 29.77

See More

52-Week High 36.44
Last Price 32.32
Fibonacci 61.8% 28.38
Fibonacci 50% 25.90
Fibonacci 38.2% 23.41
52-Week Low 15.35

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.